The EIC Accelerator is a strong fit for this pre-seed AI/biotech startup, offering non-dilutive grant funding up to €2.5M plus potential equity investment. The venture's deep tech focus on drug resistance prediction and validated proof-of-concept aligns with the programme's high-risk, high-potential criteria, and the founder's EU location (Île-de-France) meets geographic requirements.